IVAX Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
Diagnostic reagent, instrumentation and software firm announces Sept. 2 that a group of purchasers controlled by industry entrepreneurs Paul Kennedy and Patrice Debregeas have purchased the approximately 72% of Ivax shares owned by Teva Pharmaceutical Industries for $14 million, or $0.70 per share. Kennedy and Debregeas will join Ivax's board of directors and Kennedy is expected to lead the firm's executive management team. Kennedy and Debregeas plan to expand the menu of test kits that Ivax offers in the U.S. and Italy to include other infectious diseases and autoimmune testing sectors